Literature DB >> 18845565

2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55.

Saori Oka1, Toshinobu Toshida, Kanako Maruyama, Keisuke Nakajima, Atsushi Yamashita, Takayuki Sugiura.   

Abstract

GPR55 is a G protein-coupled receptor. Recently, we obtained evidence that lysophosphatidylinositol (LPI) is a possible endogenous ligand for GPR55. However, no information is currently available concerning the biological activities of the individual molecular species of LPI. Furthermore, little is known concerning the levels as well as the molecular species of LPI in mammalian tissues. In this study, we first examined whether LPI is present in rat brain. We found that rat brain contains 37.5 nmol/g tissue of LPI; the most predominant fatty acyl moiety is stearic acid (50.5%) followed by arachidonic acid (22.1%). We next compared the biological activities of various molecular species of LPI and related molecules using HEK293 cells expressing GPR55. We found that the level of biological activity of the 2-arachidonoyl species is markedly higher than those of others. These results strongly suggest that the 2-arachidonoyl species of LPI is the true natural ligand for GPR55.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18845565     DOI: 10.1093/jb/mvn136

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  63 in total

Review 1.  Pharmacological characterization of GPR55, a putative cannabinoid receptor.

Authors:  Haleli Sharir; Mary E Abood
Journal:  Pharmacol Ther       Date:  2010-03-16       Impact factor: 12.310

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator.

Authors:  X Zhang; Y Maor; J F Wang; G Kunos; J E Groopman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

4.  Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55.

Authors:  Evangelia Kotsikorou; Diane L Lynch; Mary E Abood; Patricia H Reggio
Journal:  Chem Phys Lipids       Date:  2010-12-24       Impact factor: 3.329

5.  Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands.

Authors:  Evangelia Kotsikorou; Karla E Madrigal; Dow P Hurst; Haleli Sharir; Diane L Lynch; Susanne Heynen-Genel; Loribelle B Milan; Thomas D Y Chung; Herbert H Seltzman; Yushi Bai; Marc G Caron; Larry Barak; Mary E Abood; Patricia H Reggio
Journal:  Biochemistry       Date:  2011-06-01       Impact factor: 3.162

Review 6.  Endocannabinoid signaling pathways: beyond CB1R and CB2R.

Authors:  Roger Gregory Biringer
Journal:  J Cell Commun Signal       Date:  2021-05-12       Impact factor: 5.782

7.  Neuromolecular Mechanisms of Cannabis Action.

Authors:  Yousra Adel; Stephen P H Alexander
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  A homology modeling study toward the understanding of three-dimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55.

Authors:  Orgil Elbegdorj; Richard B Westkaemper; Yan Zhang
Journal:  J Mol Graph Model       Date:  2012-10-23       Impact factor: 2.518

9.  Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations.

Authors:  Saida Mebarek; Abdelkarim Abousalham; David Magne; Le Duy Do; Joanna Bandorowicz-Pikula; Slawomir Pikula; René Buchet
Journal:  Int J Mol Sci       Date:  2013-03-01       Impact factor: 5.923

10.  GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells.

Authors:  Alexander Bondarenko; Markus Waldeck-Weiermair; Shamim Naghdi; Michael Poteser; Roland Malli; Wolfgang F Graier
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.